Roche – Innovation in Oncology & Biotech
Roche
F. Hoffmann-La Roche AG (Roche) is a Swiss pharmaceutical company headquartered in Basel, founded in 1896 by Fritz Hoffmann-La Roche. Its shares trade on the SIX Swiss Exchange as part of the SMI index; slightly more than half of the voting shares are held by descendants of the Hoffmann and Oeri families.
Roche has two divisions, Pharmaceuticals and Diagnostics. The group includes the US biotech company Genentech, wholly owned by Roche since 2009, and Japan's Chugai, in which Roche holds a controlling stake. Its pharmaceutical business focuses on oncology, immunology, neuroscience, ophthalmology and infectious diseases.
Roche is one of the pioneers of biological cancer therapy, with monoclonal antibodies such as Avastin (bevacizumab), Herceptin (trastuzumab) and MabThera (rituximab). In Turkey, Avastin is sold under the name Altuzan. Zelboraf (vemurafenib) is a BRAF kinase inhibitor approved in 2011 for metastatic melanoma with a BRAF V600 mutation. Vesanoid (tretinoin) is a vitamin A derivative used in acute promyelocytic leukaemia; in a number of countries the rights to it have passed to the German company Cheplapharm.
Unifarm carries Roche's oncology medicines Altuzan 400 (bevacizumab), Zelboraf (vemurafenib) and Vesanoid (tretinoin).